The Potential of Alpha-Lipoic Acid Supplementation for Non-Alcoholic Fatty Liver Disease: A Systematic Review
), Nikolaus Tobian(2), Hendri Tanjaya(3), Riki Tenggara(4), Luse Loe(5),
(1) School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia Department of Internal Medicine, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
(2) School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
(3) School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
(4) Department of Internal Medicine, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
(5) Department of Internal Medicine, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
Corresponding Author
Abstract
Background: Insulin resistance, genetic susceptibility, oxidative stress, and inflammation lead to the development of non-alcoholic fatty liver disease (NAFLD). Alpha lipoic acid (ALA) has demonstrated benefits in enhancing insulin sensitivity and reducing inflammatory reactions in both human and animal studies. This study aims to determine the effectiveness of ALA against NAFLD.
Methods: Detailed searches were conducted across several databases, including PubMed, CENTRAL, Europe PMC (medRxiv and bioRxiv), EBSCOhost (Medline), and ProQuest, using keywords such as lipoic acid, metabolic-associated fatty liver disease, steatohepatitis, and non-alcoholic fatty liver disease. Risk of bias was assessed using the Cochrane risk-of-bias tool for randomized trials.
Result: Four studies were included in which the ALA effect was compared with placebo or no intervention. A significant reduction in BMI (p<0.001), lipid profiles (p<0.05), glycemic markers (p<0.05), liver enzymes (p<0.05), oxidative stress (p<0.05), and fibrosis score (p<0.05) was seen in NAFLD patients with ALA supplementation.
Conclusion: This study shows that ALA may help manage NAFLD. However, further research is required to establish robust evidence.
Keywords
References
Qian Y, Sun B, Zhang Y, Zhang M, Jiao X, Lai L, et al. A clinical and laboratory-based nomogram for predicting nonalcoholic fatty liver disease in non-diabetic adults: a cross-sectional study. Ann Palliat Med 2022;11(7):2349–2359.
Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the pathogenesis, genetic, and non-Invasive clinical, biochemical, and scoring methods in the assessment of NAFLD. Int J Environ Res Public Health 2019;16(19):3570.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67(1):123–33.
Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. The Lancet 2017;390(10113):2627–42.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328-357.
Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(7):1999-2014.
Younossi ZM, Tampi R, Zhou C, et al. MAFLD: A new term for NAFLD in 2020—Implications for clinical practice and research. J Hepatol 2020;73(6):1222-1230.
Basu PP, Shah NJ, Aloysius MM, Brown Jr. RS. Effect of vitamin E and alpha lipoic acid in nonalcoholic fatty liver disease: A randomized, placebo-controlled, open-label, prospective clinical trial (VAIN trial). Open J. Gastroenterol 2014;04(05):199–207.
Clare K, Dillon JF, Brennan PN. Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD. J Clin Transl Hepatol 2022;10(5):939–46.
Ko C-Y, Lo YM, Xu J-H, Chang W-C, Huang D-W, Wu J S-B, et al. Alpha-lipoic acid alleviates NAFLD and triglyceride accumulation in liver via modulating hepatic NLRP3 inflammasome activation pathway in type 2 diabetic rats. Food Sci Nutr 2021;9(5):2733–42.
Rahmanabadi A, Mahboob S, Amirkhizi F, Hosseinpour-Arjmand S, Ebrahimi-Mameghani M. Oral α-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features. Food Funct 2019;10(8):4941–52.
Yang Y, Li W, Liu Y, Sun Y, Li Y, Yao Q, et al. Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxO1 and Nrf2 via the SIRT1/LKB1/AMPK pathway. J Nutr Biochem 2014;25(11):1207–17.
Zonooz SR, Hasani M, Morvaridzadeh M, Pizarro AB, Heydari H, Yosaee S, et al. Effect of alpha-lipoic acid on oxidative stress parameters: A systematic review and meta-analysis. J Funct Foods 2021;87:104774.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;n71.
Alver Prasetya, Nikolaus Tobian, Hendri Tanjaya, Luse Loe, Riki Tenggara. The efficacy of alpha lipoic acid in nonalcoholic liver disease and nonalcoholic steatohepatitis: A systematic review and meta-analysis of clinical trials. PROSPERO 2023 CRD42023453955 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023453955.
Higgins JPT, Savovic J, Page MJ, Sterne JAC. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0). Cochrane 2016.
Tutunchi H, Arefhosseini S, Ebrahimi-Mameghani M. Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial. Clin Nutr ESPEN 2023;54:412–20.
Hosseinpour-Arjmand S, Amirkhizi F, Ebrahimi-Mameghani M. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 2019;44(2):258–67.
Amirkhizi F, Hamedi-Shahraki S, Hosseinpour-Arjmand S, Ebrahimi-Mameghani M. The effect of alpha-lipoic acid on liver function and metabolic markers in obese patients with non-alcoholic fatty liver disease: A double - blind randomized controlled trial. Iran. Red Crescent Med J 2018;20(3):1-11.
Gianturco V, Troisi G, Bellomo A, Bernadini S, D'Ottavio E, Formosa V, et al. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. Hepatol Int 2013;7(2):570–6.
Amirkhizi F, Hamedi-Shahraki S, Hosseinpour-Arjmand S, Vaghef-Mehrabany E, Ebrahimi-Mameghani M. Effects of alpha-lipoic acid supplementation on oxidative stress status in patients with non-alcoholic fatty liver disease: A randomized, double blind, placebo-controlled clinical trial. Iran Red Crescent Med J 2018;20(9):e67615.
Ma Q, Li Y, Fan Y, Zhao L, Wei H, Ji C, et al. Molecular mechanisms of lipoic acid protection against aflatoxin B1-induced liver oxidative damage and inflammatory responses in Broilers. Toxins 2015;7(12):5435–47.
Kucukgoncu S, Zhou E, Lucas K, Tek C. Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obes Rev 2017;18(5):594–601.
Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Martínez JA, Moreno-Aliaga MJ. Effects of lipoic acid on AMPK and adiponectin in adipose tissue of low- and high-fat-fed rats. Eur J Nutr 2013;52(2):779–87.
Akbari M, Ostadmohammadi V, Lankarani KB, Tabrizi R, Kolahdooz F, Khatibi SR, et al. The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. Metabolism 2018;87:56–69.
Cummings BP, Stanhope KL, Graham JL, Evans JL, Baskin DG, Griffen SC, et al. Dietary fructose accelerates the development of diabetes in UCD-T2DM rats: amelioration by the antioxidant, α-lipoic acid. Am J Physiol Regul Integr Comp Physiol 2010;298(5):R1343–R1350.
Lee WJ, Song K-H, Koh EH, Won JC, Kim HS, Park HS, et al. α-Lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun 2005;332(3):885–91.
Kuo Y-T, Lin T-H, Chen W-L, Lee H-M. Alpha-lipoic acid induces adipose triglyceride lipase expression and decreases intracellular lipid accumulation in HepG2 cells. Eur J Pharmacol 2012;692(1–3):10–18.
Kravchenko LV, Aksenov IV, Nikitin NS, Guseva GV, Avrenyeva LI, Trusov NV, et al. Lipoic acid exacerbates oxidative stress and lipid accumulation in the liver of wistar rats fed a hypercaloric choline-deficient diet. Nutrients 2021;13(6):1999.
Reis R, Kolci K, Bahcivan İ, Coskun GP, Sipahi H. Alpha-lipoic acid modulates the oxidative and inflammatory responses induced by traditional and novel tobacco products in human liver epithelial cells. Chem Biodivers 2023;20(3):e202200928.
Longhitano L, Distefano A, Musso N, Bonacci P, Orlando L, Giallongo S, et al. Lipoic acid reduces mitochondrial unfolded protein response and attenuates oxidative stress and aging in an in vitro model of non-alcoholic fatty liver disease. J Transl Med 2024;22(1):82.
Stanković MN, Mladenović D, Ninković M, Ethuričić I, Sobajić S, Jorgačević B, et al. The effects of α-lipoic acid on liver oxidative stress and free fatty acid composition in methionine-choline deficient diet-induced NAFLD. J Med Food 2014;17(2):254–61.
Zwierz M, Chabowski A, Sztolsztener K. α-Lipoic acid – a promising agent for attenuating inflammation and preventing steatohepatitis in rats fed a high-fat diet. Arch Biochem Biophys 2023;750:109811.
Morsy MA, Younis NS, El-Sheikh AAK, Al Turaifi FH, El-Daly M, Mohafez OM. Protective mechanisms of piperine against acetaminophen-induced hepatotoxicity may be mediated through TGFBRAP1. Eur Rev Med Pharmacol Sci 2020;24(19):10169–80.
Abdou RH, Abdel-Daim MM. Alpha-lipoic acid improves acute deltamethrin-induced toxicity in rats. Can J Physiol Pharmacol 2014;92(9):773–9.
Xia X, Su C, Fu J, Zhang P, Jiang X, Xu D, et al. Role of α-lipoic acid in LPS/d-GalN induced fulminant hepatic failure in mice: Studies on oxidative stress, inflammation and apoptosis. Int Immunopharmacol 2014;22(2):293–302.
Min A-K, Kim M-K, Kim H-S, Seo H-Y, Lee K-U, Kim J-G, et al. Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice. Life Sci 2012;90(5–6):200–5.
El-Maadawy W, Hammam O, Seif el-Din S, El-Lakkany N. α-Lipoic acid modulates liver fibrosis: A cross talk between TGF-β1, autophagy, and apoptosis. Hum Exp Toxicol 2020;39(4):440–50.
Article Metrics
Abstract View
: 659 times
Download : 659 times
DOI: 10.24871/2632025204-211
Refbacks
- There are currently no refbacks.
